Alunbrig(brigatinib)
Alunbrig (brigatinib) is a small molecule pharmaceutical. Brigatinib was first approved as Alunbrig on 2017-04-28. It is used to treat non-small-cell lung carcinoma in the USA. It has been approved in Europe to treat non-small-cell lung carcinoma.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| neoplasms | D009369 |
| respiratory tract diseases | D012140 |
Trade Name
FDA
EMA
Alunbrig
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| alunbrig | New Drug Application | 2024-10-24 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| non-small-cell lung carcinoma | — | D002289 | — |
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
BRIGATINIB, ALUNBRIG, TAKEDA PHARMS USA | |||
| 2027-05-22 | ODE-300 | ||
| 2024-04-28 | ODE-142 | ||
HCPCS
No data
Clinical
Clinical Trials
46 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Non-small-cell lung carcinoma | D002289 | — | — | 1 | 5 | 1 | — | 6 | 13 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Lung neoplasms | D008175 | — | C34.90 | 1 | 1 | — | — | 3 | 5 |
| Lymphoma | D008223 | — | C85.9 | 2 | 2 | — | — | 2 | 4 |
| Neoplasms | D009369 | — | C80 | 3 | 2 | — | — | — | 3 |
| Large-cell lymphoma anaplastic | D017728 | — | C84.6 | 2 | 2 | — | — | — | 2 |
| Plasma cell granuloma | D006104 | — | — | 2 | 2 | — | — | — | 2 |
| Neurofibromatosis 2 | D016518 | — | Q85.02 | — | 1 | — | — | — | 1 |
| Acoustic neuroma | D009464 | — | — | — | 1 | — | — | — | 1 |
| Meningioma | D008579 | EFO_0003098 | D32.9 | — | 1 | — | — | — | 1 |
| Ependymoma | D004806 | — | — | — | 1 | — | — | — | 1 |
| Neurofibromatosis 1 | D009456 | — | Q85.01 | — | 1 | — | — | — | 1 |
Show 4 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Disease progression | D018450 | — | — | 1 | — | — | — | — | 1 |
| Gene rearrangement | D015321 | — | — | 1 | — | — | — | — | 1 |
| Carcinoma | D002277 | — | C80.0 | 1 | — | — | — | — | 1 |
| Healthy volunteers/patients | — | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Brigatinib |
| INN | brigatinib |
| Description | Brigatinib, sold under the brand name Alunbrig among others, is a small-molecule targeted cancer therapy being developed by Ariad Pharmaceuticals, Inc. Brigatinib acts as both an anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR) inhibitor.
|
| Classification | Small molecule |
| Drug class | tyrosine kinase inhibitors |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | COc1cc(N2CCC(N3CCN(C)CC3)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1 |
Identifiers
| PDB | — |
| CAS-ID | 1197953-54-0 |
| RxCUI | — |
| ChEMBL ID | CHEMBL3545311 |
| ChEBI ID | — |
| PubChem CID | 68165256 |
| DrugBank | — |
| UNII ID | HYW8DB273J (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Alunbrig – Takeda
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 2,864 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
2,912 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use